Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histological proof of muscle-invasive transitional cell carcinoma of the bladder (stage II-III) with no evidence of metastatic disease (focal squamous and/or adenocarcinoma differentiation allowed, sarcomatoid and small-cell components not allowed). Patient with any degree of fixation of the pelvic sidewall are not eligible.~* Must be willing to undergo a cystoscopy if tumor block is not available prior to registration for protocol therapy.~* Eligible for radical cystectomy as per the attending urologist.~* Prior radiation therapy to bone marrow is allowed to \< 25% of the marrow, and must be completed at least 6 months prior to registration for protocol therapy~* Written informed consent and HIPAA authorization for release of personal health information.~* Age \> 18 years at the time of consent.~* Females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 6 weeks after treatment discontinuation.~* Females of childbearing potential must have a negative pregnancy test within 7 days prior to being registered for protocol therapy.~Exclusion Criteria:~* No prior radiotherapy to the pelvis.~* No prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, Gleason\< grade 7 prostate cancers, or other cancer for which the patient has been disease-free for at least 5 years.~* No treatment with any investigational agent within 30 days prior to registration for protocol therapy.~* No cerebrovascular accident or transient ischemic attack within 6 months prior to registration for protocol therapy.~* No evidence of pulmonary embolism within 6 months prior to registration for protocol therapy.~* No uncontrolled hypertension (\>150/100 mm Hg despite optimal medical therapy).~* No evidence of ongoing cardiac dysrhythmias of NCI CTCAE Version 3.0 grade 2.~* No history of uncontrolled/untreated thyroid dysfunction.~* No prolonged QTc interval (\> 450 msec) on pre-entry electrocardiogram obtained within 28 days prior to being registered on study.~* Patients on warfarin (\>2mg) for thrombosis must be able and willing to switch to low molecular weight heparin prior to registration for protocol therapy.~* No use of drugs having proarrhythmic potential (terfenadine, quinidine, procainamide, disopyramide, sotalol, probucol, bepridil, haloperidol, risperidone, indapamide and flecainide) within 7 days prior to registration for protocol therapy.~* No use of CYP3A4 inhibitors (see section 5.3 for a list) within 7 days of registration for protocol therapy.~* No use of CYP3A4 inducers (see section 5.3 for a list) within 14 days of registration for protocol therapy.~* No use of amiodarone (CYP3A4 inhibitor) within 6 months of registration for protocol therapy.~* Females must not be breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental Treatment (Type: EXPERIMENTAL): Neoadjuvant cisplatin, gemcitabine and sunitinib malate followed by radical cystectomy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues